provide additional guidance to obstetric care providers regarding treatment of these 24 women. While this statement differs in some respects from the ACOG Practice Bulletin, 25 the SMFM Publications Committee acknowledges that this difference is based on the 26 values placed by different experts and providers on the evidence available in the medical 27 literature and is not meant to represent an exclusive course of management. 28
Although neither insulin, metformin, nor glyburide use during pregnancy has been 29 associated with newborn birth defects (11), long-term metabolic effects of offspring 30 exposed in utero to oral hypoglycemic agents are less well known. Because insulin does 31 not cross the placenta, and based on almost 100 years of experience of use in pregnancy, 32 most experts concur that insulin is safe for the fetus and newborn, and the American 33
Diabetes Association (ADA) endorses insulin as a first-line treatment for GDM (12). 34
However, insulin requires multiple daily injections, which can reduce compliance. 35
Studies comparing insulin to metformin have reported a strong patient preference for the 36 oral agent (13). In addition, insulin use is associated with an increased risk of 37 hypoglycemia, although hypoglycemia in women with GDM is not common and 38 typically is not severe. In a 2017 Cochrane review, the rate of maternal hypoglycemia 39 was not significantly higher in women treated with insulin versus oral agents (RR 3.01, 40 95% CI 0.74 to 12.27), and several studies report no maternal hypoglycemia in either 41 group (10). 42
Metformin is an oral biguanide that primarily acts to decrease hepatic glucose 43 production by inhibiting gluconeogenesis. It also increases glucose uptake in peripheral 44 tissues and decreases glucose absorption in the gastrointestinal tract (14). Compared with 45 insulin, metformin use in GDM is associated with less maternal weight gain, lowergestational age at delivery, less gestational hypertension, and less neonatal hypoglycemia(7, 15). Maternal side effects of metformin are largely gastrointestinal and include 48 transient anorexia, nausea, and loose stools, causing 2% of pregnant women to 49 discontinue use in one study (13) . 50
Unlike insulin, metformin readily crosses the placenta, resulting in fetal 51 concentrations similar to those in the maternal circulation and raising concern for impact 52 on neonatal outcomes as well as long-term effects (16). Reassuringly, in one study, 53 children aged 2 years who were exposed in utero to metformin versus insulin had similar 54 overall body fat, but more subcutaneous fat; this effect is postulated to mean that 55 metformin treatment may lead to a more favorable pattern of fat distribution compared to 56 insulin (17). In this same cohort, these children were also reported to have comparable 57 neurodevelopmental outcomes as compared with those exposed to insulin (18). Thus, 58 although studies on long-term outcomes in offspring exposed to metformin in utero are 59 more limited than those regarding insulin, available data are reassuring (19). 60
Glyburide is an oral sulfonylurea that primarily acts by increasing insulin 61 secretion from the pancreas (20). Although initial studies did not detect glyburide in cord 62 serum of infants whose mothers were treated with glyburide for GDM (21), subsequent 63 studies suggest that it is present in concentrations averaging approximately 70% of 64 maternal levels (22). To date, there are no studies evaluating the long-term effects on 65 metabolic or neurodevelopmental outcomes in offspring exposed to glyburide in utero. 66
Since the introduction of oral hypoglycemic agents, their use in pregnancy has 67 increased (23). One study of a cohort of privately insured U.S. women showed that from 68 this increase in use include the fact that, compared to insulin, oral hypoglycemic agentshave a lower cost and higher patient acceptance, which may increase patient satisfaction 71 and/or compliance (13). 72
Because of its almost limitless ability to escalate and titrate doses to control blood 73 glucose, insulin is presumed to be the most effective means to control hyperglycemia 74 associated with GDM. In more than one-half of GDM pregnancies, oral hypoglycemic 75 agents as monotherapy result in adequate glycemic control. In clinical trials comparing 76 glyburide and metformin to insulin, the need for adjunctive insulin to achieve glycemic 77 control ranges between 26% and 46% for women using metformin and 4% and 16% for 78 women using glyburide (13, 21, 25, 26). In a randomized controlled trial comparing 79 metformin to glyburide, women using metformin were twice as likely to need insulin as 80 women using glyburide (RR 2.1, 95% CI 1.2-3.9) [25] . analyzed 7 studies comparing glyburide to insulin (798 subjects), 6 comparing metformin 96 to insulin (1362 subjects), and 2 comparing glyburide to metformin (349 subjects) [7] . 97
Compared with both insulin and metformin, glyburide was associated with higher birth 98 weight and more frequent macrosomia and neonatal hypoglycemia. Metformin was 99 associated with less maternal weight gain and fewer LGA infants but higher rates of 100 preterm birth (pooled risk ratio 1.50, 95% CI 1.04-2.16). The authors concluded that 101 glyburide is inferior to both insulin and metformin, while metformin (plus insulin when 102 required) performs slightly better than insulin (7). 103
More recently, Farrar et al. analyzed 11 studies comparing metformin to insulin 104 (2365 subjects), 9 studies comparing glyburide to insulin (981 subjects), and 4 studies 105 comparing glyburide to metformin (508 subjects). The authors concluded that metformin 106 was associated with the lowest risk of neonatal hypoglycemia, macrosomia, LGA, 107 preeclampsia, and neonatal intensive care unit (NICU) admission and comparable 108 preterm birth risk. Although acknowledging weaknesses in the data, they describe a 109 general "trend" in favor of metformin over insulin or glyburide and suggest either 110 metformin or insulin if glucose levels are not adequately controlled with dietary and 111 lifestyle modifications (8). Finally, two Cochrane Reviews in 2017 addressed oral 112 hypoglycemic agents and insulin for management of GDM (9, 10). In these reviews, the 113 authors concluded that there was insufficient high-quality evidence to assess whether oneoral hypoglycemic agent is superior to another or to insulin, and note that the choice touse one or the other may reasonably be based on physician or maternal preference, 116 availability, or the severity of GDM (9, 10). 117
It should be also noted that both maternal and perinatal outcomes are influenced 118 not only by the type of agent that is used to treat GDM, but by many other variables, 119 including indications for screening (who is screened), timing of screening, type of 120 screening (one-versus two-step screening and the screening protocol chosen), criteria for 121 GDM diagnosis, criteria to start therapy after failure of dietary and lifestyle interventions 122 alone, dosage and frequency of initial therapy, frequency of glucose monitoring, target 123 glucose values, criteria for pharmacologic therapy dosage adjustment, and criteria for 124 adding or switching pharmacologic therapy. 125
Given the available data, the SMFM Publications Committee concludes that in 126 women with GDM in which hyperglycemia cannot adequately be controlled with medical 127 nutrition therapy, metformin is a reasonable and safe first-line pharmacologic alternative 128 to insulin, recognizing that one-half of women will still require insulin to achieve 129 glycemic control. While concerns have been raised for more frequent adverse neonatal 130 outcomes with glyburide, including macrosomia and hypoglycemia, the evidence of 131 benefit of one oral agent over the other remains limited. Clearly, further data are needed 132 to establish long-term safety of these agents. 133 134
